831 related articles for article (PubMed ID: 25482933)
21. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
22. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
23. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Kim HG; Hien TT; Han EH; Hwang YP; Choi JH; Kang KW; Kwon KI; Kim BH; Kim SK; Song GY; Jeong TC; Jeong HG
Br J Pharmacol; 2011 Mar; 162(5):1096-108. PubMed ID: 21054339
[TBL] [Abstract][Full Text] [Related]
24. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
25. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
27. Ascorbate promotes the cellular accumulation of doxorubicin and reverses the multidrug resistance in breast cancer cells by inducing ROS-dependent ATP depletion.
Liu Y; Zhang L; Ma Z; Tian L; Liu Y; Liu Y; Chen Q; Li Y; Ma E
Free Radic Res; 2019 Jul; 53(7):758-767. PubMed ID: 31170853
[TBL] [Abstract][Full Text] [Related]
28. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
29. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
[TBL] [Abstract][Full Text] [Related]
30. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
31. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
32. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells.
Wang Y; Ma G; Wang Q; Wen M; Xu Y; He X; Zhang P; Wang Y; Yang T; Zhan P; Wei G
Molecules; 2013 Dec; 19(1):159-76. PubMed ID: 24368600
[TBL] [Abstract][Full Text] [Related]
33. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
34. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
35. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
36. Metformin enhances doxorubicin sensitivity via inhibition of doxorubicin efflux in P-gp-overexpressing MCF-7 cells.
Shafiei-Irannejad V; Samadi N; Yousefi B; Salehi R; Velaei K; Zarghami N
Chem Biol Drug Des; 2018 Jan; 91(1):269-276. PubMed ID: 28782285
[TBL] [Abstract][Full Text] [Related]
37. Alisol F 24 Acetate Enhances Chemosensitivity and Apoptosis of MCF-7/DOX Cells by Inhibiting P-Glycoprotein-Mediated Drug Efflux.
Pan G; Li T; Zeng Q; Wang X; Zhu Y
Molecules; 2016 Feb; 21(2):. PubMed ID: 26861264
[TBL] [Abstract][Full Text] [Related]
38. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
[TBL] [Abstract][Full Text] [Related]
39. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
40. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells.
Fu LW; Zhang YM; Liang YJ; Yang XP; Pan QC
Eur J Cancer; 2002 Feb; 38(3):418-26. PubMed ID: 11818209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]